TY - JOUR T1 - Geographic partitioning of dengue virus transmission risk in Florida JF - medRxiv DO - 10.1101/2021.09.24.21264065 SP - 2021.09.24.21264065 AU - Caroline J. Stephenson AU - Heather Coatsworth AU - Christy M. Waits AU - Nicole M. Nazario-Maldonado AU - Derrick K. Mathias AU - Rhoel R. Dinglasan AU - John A. Lednicky Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/09/27/2021.09.24.21264065.abstract N2 - Dengue viruses (DENVs) cause the greatest public health burden globally among the arthropod-borne viruses. DENV transmission risk has also expanded from tropical to subtropical regions due to the increasing range of its principal mosquito vector, Aedes aegypti. Focal out-breaks of dengue fever (dengue) in the state of Florida (FL) in the USA have increased since 2009. However, little is known about the competence of Ae. aegypti populations across different regions of FL to transmit DENVs. To understand the effects of DENV genotype and serotype variations on vector susceptibility and transmission potential in FL, we orally infected a colony of Ae. aegypti (Orlando/ORL) with laboratory and wild type DENV-1 through -4. Wild type DENVs were more infectious to and transmissible by ORL mosquitoes. We used these same DENVs to examine natural Ae. aegypti populations to determine whether spatial distributions correlated with differential vector competence. Vector competence across all DENV serotypes was greater for mosquitoes from areas with the highest dengue incidence in south FL compared to north FL. Vector competence for wild type DENVs was significantly higher, revealing that transmission risk is influenced by virus/vector combinations. These data support a targeted mosquito-plus-pathogen screening approach to more accurately estimate DENV transmission risk.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was supported in part by the United States Centers for Disease Control (CDC) Grant 1U01CK000510-03: Southeastern Regional Center of Excellence in Vector-Borne Diseases: The Gateway Program. The CDC did not have a role in the design of the study, the collection, analysis, or in-terpretation of data, nor in writing the manuscript. Support was also pro-vided by the University of Florida Emerging Pathogens Institute, the University of Florida Preeminence Initiative through the UF College of Veterinary Medicine and the University of Florida Graduate Student Funding Award.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not applicableAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available in the manuscript ER -